Completed PHASE3 INTERVENTIONAL 2-arm NCT00469326

Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study (TIPS)

Sponsor: University Hospital, Motol

Updated 6 times since 2017 Last updated: Jan 26, 2009 Started: Apr 30, 2005 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Coronary Artery Disease and is currently completed. University Hospital, Motol leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Motol

Data source: University Hospital, Motol

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Prague, Czechia